S95012 concentrate solution for infusion 400mg/ 16 ml, Gazyvaro 1,000 mg concentrate for solution for infusion. clinical trials

A first in human Phase 1/2 open-label, multicenter, dose escalation and expansion study of PRS-344/S095012 in patients with solid tumors.

This study is testing a new medicine, PRS-344/S095012, combined with another treatment, Gazyvaro, for people with solid tumours. It aims to find the right dose and see how safe and effective the combination is.